OcuNexus Therapeutics Stock

ocunexus.comHealthcareFounded: 1900Funding to Date: $144.36MM

Ocunexus Therapeutics is a biotechnology company focused on inflammasome modulation for treatment of Dry Age-related Macular Degeneration and Diabetic Retinopathy.

Register for Details

For more details on financing and valuation for OcuNexus Therapeutics, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

By registering, you agree to the Forge Terms of Use. Already registered? Click here to log in

Enterprise Value (based on primary financings)

Enterprise Value

View Enterprise Value for OcuNexus Therapeutics.

Register Today

Team

Management Team

David Pool
Chief Financial Officer
Bradford Duft JD
Co-Founder, President & Board Member
Brian Levy
Chief Executive Officer
Anthony Phillips Ph.D
Medical & Pre-Clinical Consultant
Tracey Sunderland
Chief Operating Officer
Colin Green Ph.D
Scientific Co-Founder & Advisor
David Becker Ph.D
Scientific Co-Founder

Board Members

Howard Greene
Geoffrey Brooke MD
GBS Venture Partners
Bradford Duft JD
Inna Eitan
RusnanoMedInvest
James Blair Ph.D
Domain Associates
James Mervis JD
Mikhail Getman Ph.D
RusnanoMedInvest
Rajiv Shukla
Frank Spurway

Other companies like OcuNexus Therapeutics in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.6B
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$150MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$296.3MM
Sector
Last Round Est. Valuation
$4.8B